Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19

Alexander Kroemer; Khalid Khan; Matthew Plassmeyer; Oral Alpan; M A Haseeb; Raavi Gupta; Thomas M Fishbein

doi:10.1016/j.jhep.2020.06.034

Inflammasome activation and pyroptosis in lymphopenic liver patients with COVID-19

J Hepatol. 2020 Nov;73(5):1258-1262. doi: 10.1016/j.jhep.2020.06.034. Epub 2020 Jul 6.

Authors

Alexander Kroemer¹, Khalid Khan², Matthew Plassmeyer³, Oral Alpan³, M A Haseeb⁴, Raavi Gupta⁴, Thomas M Fishbein²

Affiliations

¹ MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center. Electronic address: alexander.h.kroemer@gunet.georgetown.edu.
² MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital and the Center for Translational Transplant Medicine, Georgetown University Medical Center.
³ Section on Immunopathogenesis, Amerimmune.
⁴ SUNY Downstate Health Sciences University, Departments of Pathology and Cell Biology, Brooklyn, New York.

No abstract available

Keywords: COVID-19; Caspase-1; Chronic liver disease; Comorbidities; Inflammasome; Liver cirrhosis; Liver transplantation; Lymphopenia; Pyroptosis; T cells.

Publication types

Letter
Comment

MeSH terms

Betacoronavirus
COVID-19
Caspase 1
Coronavirus Infections*
Humans
Inflammasomes*
NLR Family, Pyrin Domain-Containing 3 Protein
Pandemics*
Pneumonia, Viral*
Pyroptosis*
Retrospective Studies
SARS-CoV-2

Substances

Inflammasomes
NLR Family, Pyrin Domain-Containing 3 Protein
Caspase 1